

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lin, et al.

Serial No.:

08/182,183

Group Art Unit No.:

1647

Filed:

May 23, 1994

Examiner: N/A

For:

Glial Cell Line-Derived Neurotrophic Factor

(As Amended)

Docket No.:

S-225E

**STATUS INQUIRY** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sirs:

Applicants in the above referenced case received a Notice from the Office of Petitions, Paper No. 61, mailed June 27, 2003, granting our petition filed January 21, 2003, to revive the above-identified application.

Since that time, Applicants have received no further communication from the Patent and Trademark Office regarding this application. It would be appreciated if the Office would advise Applicants of the current status of this application.

Please send all future correspondence to:

US Patent Operations/RLS Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799 Respectfully submitted

Robert L. Sharp

Attorney/Agent for Applicant(s) Registration No.: 45,60934,688

Phone: (805) 447-5992

Date: September 11, 2003

**CERTIFICATE OF MAILING** 

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.